Trevena, Inc. (TRVN) Covered Calls
Trevena Inc is a clinical stage biopharmaceutical company. The Company discovers, develops and commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.
There are no covered calls available for Trevena, Inc..
Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Trevena, Inc. is a clinical stage biopharmaceutical company, which discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. Its product pipeline consists of TRV027, which is an intravenous drug for the treatment of acute heart failure in combination with standard diuretic therapy; TRV130, which is an intravenous G protein biased ligand that targets the mu opioid receptor; TRV734, which is a follow-on program to the TRV130 mu opioid biased ligand program, and is expected to have pharmacokinetics amenable to chronic oral administration; and Delta Opiod. The company was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | RKLB covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | LUNR covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | NMRA covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | CRVS covered calls | |
Want more examples? TRVG Covered Calls | TRX Covered Calls
